BACKGROUND AND OBJECTIVE:TZP-101 is a selective, small molecule ghrelin receptor agonist in clinical development for the treatment of gastric motility disorders. The objectives of this study was to assess pharmacokinetic parameters of TZP-101 after multiple- and single-dose administration to healthy subjects and patients with gastroparesis, respectively, and to determine the contribution of protein binding to its pharmacokinetic behaviour. METHODS: Pharmacokinetics following 30-minute intravenous infusions of single (160-600 microg/kg) doses of TZP-101 in patients with gastroparesis and multiple (80-600 mug/kg/day) doses of TZP-101 in healthy subjects were characterized. TZP-101 protein binding was measured in human, dog, rat, rabbit and monkey plasma using equilibrium dialysis. RESULTS:TZP-101 pharmacokinetic profiles were less than dose proportional in both healthy subjects and patients, most likely because of concentration-dependent protein binding. A small volume of distribution (99-180 mL/kg following single doses) and long half-life (10-20 hours) were concentration independent in both healthy subjects and patients. Systemic clearance increased with increasing dose. Incidence of adverse events was not related to dose or treatment (active vs placebo). TZP-101 binding to human plasma proteins (primarily alpha(1)-acid glycoprotein) was >/=99% between 5 and 15 mumol/L (2.7 and 8.1 microg/mL) and was significantly higher than in other species. CONCLUSIONS: The pharmacokinetic parameters of TZP-101 in patients with gastroparesis and healthy subjects are comparable and display a similar trend toward increased clearance at higher dose levels resulting in little accumulation of TZP-101 at high dose levels and after multiple dosing. Significant protein binding indicates that the fraction of free drug rather than the total plasma concentration should be taken into consideration for human risk assessment based on animal safety data. Furthermore, the concentration of unbound drug should be considered when optimizing the clinical dose.
RCT Entities:
BACKGROUND AND OBJECTIVE:TZP-101 is a selective, small molecule ghrelin receptor agonist in clinical development for the treatment of gastric motility disorders. The objectives of this study was to assess pharmacokinetic parameters of TZP-101 after multiple- and single-dose administration to healthy subjects and patients with gastroparesis, respectively, and to determine the contribution of protein binding to its pharmacokinetic behaviour. METHODS: Pharmacokinetics following 30-minute intravenous infusions of single (160-600 microg/kg) doses of TZP-101 in patients with gastroparesis and multiple (80-600 mug/kg/day) doses of TZP-101 in healthy subjects were characterized. TZP-101 protein binding was measured in human, dog, rat, rabbit and monkey plasma using equilibrium dialysis. RESULTS:TZP-101 pharmacokinetic profiles were less than dose proportional in both healthy subjects and patients, most likely because of concentration-dependent protein binding. A small volume of distribution (99-180 mL/kg following single doses) and long half-life (10-20 hours) were concentration independent in both healthy subjects and patients. Systemic clearance increased with increasing dose. Incidence of adverse events was not related to dose or treatment (active vs placebo). TZP-101 binding to human plasma proteins (primarily alpha(1)-acid glycoprotein) was >/=99% between 5 and 15 mumol/L (2.7 and 8.1 microg/mL) and was significantly higher than in other species. CONCLUSIONS: The pharmacokinetic parameters of TZP-101 in patients with gastroparesis and healthy subjects are comparable and display a similar trend toward increased clearance at higher dose levels resulting in little accumulation of TZP-101 at high dose levels and after multiple dosing. Significant protein binding indicates that the fraction of free drug rather than the total plasma concentration should be taken into consideration for human risk assessment based on animal safety data. Furthermore, the concentration of unbound drug should be considered when optimizing the clinical dose.
Authors: T L Abell; R K Bernstein; T Cutts; G Farrugia; J Forster; W L Hasler; R W McCallum; K W Olden; H P Parkman; C R Parrish; P J Pasricha; C M Prather; E E Soffer; R Twillman; A I Vinik Journal: Neurogastroenterol Motil Date: 2006-04 Impact factor: 3.598
Authors: M Binn; C Albert; A Gougeon; H Maerki; B Coulie; M Lemoyne; R Rabasa Lhoret; C Tomasetto; P Poitras Journal: Peptides Date: 2006-01-19 Impact factor: 3.750
Authors: Alex Sparreboom; Huachen Chen; Milin R Acharya; Adrian M Senderowicz; Richard A Messmann; Takashi Kuwabara; David J Venzon; Anthony J Murgo; Donna Headlee; Edward A Sausville; William D Figg Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: E Fuse; H Tanii; K Takai; K Asanome; N Kurata; H Kobayashi; T Kuwabara; S Kobayashi; Y Sugiyama Journal: Cancer Res Date: 1999-03-01 Impact factor: 12.701
Authors: Y Date; M Kojima; H Hosoda; A Sawaguchi; M S Mondal; T Suganuma; S Matsukura; K Kangawa; M Nakazato Journal: Endocrinology Date: 2000-11 Impact factor: 4.736
Authors: H Karasawa; C Pietra; C Giuliano; S Garcia-Rubio; X Xu; S Yakabi; Y Taché; L Wang Journal: Neurogastroenterol Motil Date: 2014-10-19 Impact factor: 3.598
Authors: Katrin Fischer; Brian Finan; Christoffer Clemmensen; Lex H T van der Ploeg; Matthias H Tschöp; Timo D Müller Journal: Front Nutr Date: 2015-01-12